Immunotherapy in Esophagogastric Adenocarcinoma

被引：3
|
作者：
Stein, Alexander [1 ]
Thuss-Patience, Peter [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
来源：
VISCERAL MEDICINE | 2019年 / 35卷 / 01期
关键词：
Immunotherapy; Esophagogastric adenocarcinoma; Combination; Chemotherapy; Targeted therapy; GASTROESOPHAGEAL JUNCTION CANCER; DOUBLE-BLIND; CHEMOTHERAPY; PEMBROLIZUMAB; MONOTHERAPY; NIVOLUMAB; EFFICACY; SAFETY;
D O I：
10.1159/000497292
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Immunotherapy, particular PD-1/L1 inhibition, is a relevant treatment approach in esophagogastric adenocarcinoma. To date, single-agent activity is limited to the chemotherapy refractory setting and molecularly defined subgroups. Currently, ongoing trials, which are likely to relevantly change the landscape of treatment for this disease in the next years, evaluate different combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. The German AIO study group has launched several combination trials in the perioperative, first-line, and advanced disease setting to further define the role of immunotherapy in esophagogastric adenocarcinoma. (C) 2019 S. Karger AG, Basel
引用
收藏
页码：12 / 16
页数：5
相关论文
共 50 条
  • [21] Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma-the randomized phase 2 INTEGA trial (AIO STO 0217)
    Tintelnot, Joseph
    Goekkurt, Eray
    Binder, Mascha
    Thuss-Patience, Peter
    Lorenzen, Sylvie
    Knorrenschild, Jorge Riera
    Kretzschmar, Albrecht
    Ettrich, Thomas
    Lindig, Udo
    Jacobasch, Lutz
    Pink, Daniel
    Al-Batran, Salah-Eddin
    Hinke, Axel
    Hegewisch-Becker, Susanna
    Nilsson, Sven
    Bokemeyer, Carsten
    Stein, Alexander
    BMC CANCER, 2020, 20 (01)
  • [22] Immunotherapy in Lung Cancer: A New Age in Cancer Treatment
    Corrales, Luis
    Scilla, Katherine
    Caglevic, Christian
    Miller, Ken
    Oliveira, Julio
    Rolfo, Christian
    IMMUNOTHERAPY, 2ND EDITION, 2018, 995 : 65 - 95
  • [23] Research progress in targeted therapy and immunotherapy for gastric cancer
    Li, Xuewei
    Xu, Jun
    Xie, Jun
    Yang, Wenhui
    CHINESE MEDICAL JOURNAL, 2022, 135 (11) : 1299 - 1313
  • [24] The current management and biomarkers of immunotherapy in advanced gastric cancer
    Chang, Xiaojing
    Ge, Xiaohui
    Zhang, Yufeng
    Xue, Xiaoying
    MEDICINE, 2022, 101 (21) : E29304
  • [25] Immunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series
    Sugiyama, Keiji
    Owaki, Seira
    Sato, Mariko
    Shiraishi, Kazuhiro
    Kato, Kyoko
    Kitagawa, Chiyoe
    IN VIVO, 2024, 38 (01): : 518 - 522
  • [26] Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
    Zhang, Yan
    Fan, Wenxuan
    Su, Fei
    Zhang, Xiaoling
    Du, Yunyi
    Li, Weiling
    Gao, Yangjun
    Hu, Wenqing
    Zhao, Jun
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [27] Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes
    Epistola, Raisa
    Sperandio, Rubens
    Wainberg, Zev
    Iqbal, Syma
    Chao, Joseph
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 265 - 275
  • [28] Multimodal treatment of adenocarcinoma of the esophagogastric junction
    Lordick, Florian
    Gockel, Ines
    ONKOLOGE, 2019, 25 (12): : 1086 - 1094
  • [29] Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?
    Elisa Fontana
    Elizabeth C. Smyth
    David Cunningham
    Current Treatment Options in Oncology, 2016, 17
  • [30] The postoperative complication for adenocarcinoma of esophagogastric junction
    Zhang, Hui
    Meng, Xianglin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (05) : C122 - C124
12345